Thu, Jul 24, 2014, 4:05 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • billyteex1 billyteex1 Sep 5, 2006 9:59 PM Flag

    Give me a break....

    I bought this stock from 4.40 down to 3.07. I knew it was undervalued then and now. Your the one on both sides of the fence roryae. I've was long when it flirted with 3.00 and only a few of us stayed positive. Just go back and read old postings. You ask for some new information. Supg has to give us that. I believe that Dacogen will be used as a conbination drug and that's where real growth will come. I believe Montigen pipeline will be the continued growth in the future. What I haven't seen is anything concrete posted to question that believe. I read up on all trials, listen to all conferences and give it my best judgement call on this information. I read these postings and try to remind the average investor that this 4.75 stock has accomplished what only a handfull of small companies will ever equal. This is all I can ask from myself. However give us a break and realize when you post something like let's sell and buy at 4.25...then sell yourself. I believe that's what 2 others stated to you. I'm glad that your long term and also believe that these stocks get manipulated. However, the bottom line is that I want someone to step to the plate and demonstrate why SUPG is not a turn around company. NO B/S...I've heard all the PSS comments and bought because they had no real basis to back it up with. I estimate only a 2-5% of Supg stock owners read this post. However find it very encouraging that a few more analyst's have now started to recomment SUPG. Figure a good update by MOGN about growth of Dacogen and a few more will jump on board.

8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.